← Back to Search

Tetracycline Antibiotic

Minocycline 100mg for Multiple Sclerosis (MS Trial)

Phase 3
Waitlist Available
Led By Luanne Metz, MD,FRCPC
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3,6,12,and 24 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial tests if minocycline, an antibiotic that helps control the immune system, can delay or prevent multiple sclerosis in adults who show early signs of the disease. Minocycline works by reducing brain inflammation and has been studied for its potential to treat multiple sclerosis due to its anti-inflammatory and neuroprotective properties.

Eligible Conditions
  • Multiple Sclerosis
  • Clinically Isolated Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3,6,12,and 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3,6,12,and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
proportion of participants diagnosed with multiple sclerosis according to the 2005 McDonald Criteria
Secondary study objectives
Proportion of participants diagnosed with multiple sclerosis according to the 2005 McDonald Criteria
The proportion of participants with no evidence of disease activity (NEDA)

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MinocyclineExperimental Treatment1 Intervention
Minocycline 100 mg oral twice daily for up to 24 month
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minocycline
FDA approved

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
809 Previous Clinical Trials
886,374 Total Patients Enrolled
9 Trials studying Multiple Sclerosis
407 Patients Enrolled for Multiple Sclerosis
Multiple Sclerosis Society of CanadaOTHER
15 Previous Clinical Trials
1,038 Total Patients Enrolled
15 Trials studying Multiple Sclerosis
1,038 Patients Enrolled for Multiple Sclerosis
Hotchkiss Brain Institute, University of CalgaryOTHER
11 Previous Clinical Trials
2,423 Total Patients Enrolled
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top